On February 2, Merck announced the commercial launch of its lung cancer targeted drug Tepotinib (Tepmetko®) in China, officially supplying it to hospitals and pharmacies nationwide.
Merck Announces Commercial Launch of Tepmetko® (Tepotinib) in China for METex14 Skipping Mutation-Positive NSCLC
Feb 02, 2024 08:06
CST Updated
08:06
Merck Group
Pharmaceutical R&D Developer